SCOTUS declines patents review on Enbrel drug
A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept).
AIPPI weighs in on COVID waiver
The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.
Oxford Nanopore secures Fed Circ victory in PacBio DNA suit
The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.
Invitae claims Natera infringed DNA patents
Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Dr. Reddy’s inks COVID-19 licensing deal amid furore over IP waiver
India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India.
Patent litigation: a global perspective
Patent protection is a global affair, so if you find yourself embroiled in litigation, it helps to know what benefits and challenges different jurisdictions can offer.
Mylan fails to void MSD diabetes treatment patent at PTAB
MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.
Brazil rules 10-year patent term ‘unconstitutional’
Brazil’s Supreme Court has ruled that the country’s ten-year patent term is unconstitutional.
WIPO unveils course on genetic resources in the life sciences
The World Intellectual Property Office has launched a course on IP and genetic resources in the life sciences.
Sanofi-Aventis gets $17.2m in fees from failed Amphastar suit
Sanofi-Aventis has been awarded $17.2 million in attorney fees, legal expenses and interest in a district court ruling on a failed suit levied by Amphastar Pharmaceuticals.
